Fennec Pharmaceuticals Signals Costly Push Toward Growth

Fennec Pharmaceuticals ((TSE:FRX)) has held its Q4 earnings call. Read on for the main highlights of the call.

Fennec Pharmaceuticals’ latest earnings call struck a cautiously upbeat tone as management showcased surging product sales, a fortified balance sheet, and extended U.S. exclusivity while openly acknowledging higher operating costs and revenue lumpiness. Investors were left with a story of near‑term expense pressure in exchange for what could be a powerful commercial and international growth runway.

Record Net Product Sales and Accelerating Growth

Fennec reported full‑year 2025 net product sales of $44.6 million, up about 50% from $29.6 million a year earlier, underscoring strong traction for its pediatric oncology drug. Fourth‑quarter sales jumped to $13.8 million from $7.9 million, an increase of roughly 75%, marking the fifth straight quarter of net product sales growth driven by more treated patients and broader account penetration.

Strong Q4 Operations and Fennec HEARS Momentum

Operational performance in Q4 was led by the Fennec HEARS patient support program, which delivered record levels in enrollments, prescribed and infused vials, and active patients. Conversion rates from prescription to infused patient improved from about 50% in Q1 to roughly 70% in Q4, a 20‑point gain that materially boosts revenue efficiency per script.

Balance Sheet Strengthened by Capital Raise and Debt Elimination

The company raised more than $42 million in net proceeds from public offerings during 2025 and used roughly $21.5 million to fully retire its outstanding debt. With cash and cash equivalents of $36.8 million at year‑end and no debt, management signaled that receivable collections position Fennec to generate positive operating cash flow in the first quarter of 2026.

Patent Settlement Extends U.S. Market Exclusivity

Fennec reached a settlement with Cipla that blocks generic sodium thiosulfate entry in the U.S. until September 1, 2033 under most scenarios, effectively locking in a long exclusivity runway. Management said the deal should protect PEDMARK’s commercial opportunity while also cutting back on recurring intellectual‑property related spending by several million dollars per year.

Advancing Clinical Evidence and Expert Engagement

The company is expanding its clinical footprint through investigator‑sponsored studies at City of Hope in adult testicular germ cell tumors and at Tampa General Hospital to evaluate adolescent and young adult real‑world use. In Japan, the STS‑J01 Phase II/III trial is progressing, and new retrospective head and neck cancer data in adults showed safe six‑hour post‑cisplatin administration without undermining curative treatment intent.

International Progress Through Norgine Partnership

Fennec’s partner Norgine launched PEDMARQSI in the U.K. and Germany in 2025, with a U.K. list price set around GBP 8,000, and secured approval in Switzerland. Norgine plans a further eight to ten country launches in 2026, positioning Fennec to begin seeing more meaningful royalty and milestone revenue in the second half of 2026 as European adoption builds.

Improving Reimbursement and Provider Adoption

On the access front, Fennec highlighted that its top three payers reimburse PEDMARK at roughly 95% to 100%, reducing friction in getting patients on therapy. Repeat prescribing is increasing across both academic centers and community oncology practices, suggesting deepening physician comfort and providing a base for sustained volume growth.

Rising Selling, Marketing and G&A Expenses

The growth push is not cheap, as Q4 selling and marketing costs climbed to $6.1 million from $3.9 million a year earlier, while Q4 G&A more than doubled to $8.9 million from $4.2 million. For the full year, G&A rose to $28.8 million from $23.1 million, with management pointing to higher payroll, expanded headcount, legal and IP spending, and increased equity‑based compensation as key drivers.

Higher Noncash Stock Compensation and Legal Spend

Noncash stock‑based compensation increased by about $2 million year‑over‑year, highlighting a greater use of equity to attract and retain talent during the company’s commercial build‑out. At the same time, intellectual property and broader legal expenses were significant contributors to the G&A step‑up, though management expects legal costs to moderate following the Cipla settlement.

Planned OpEx Expansion to Fund 2026 Growth

Looking ahead, Fennec plans to increase cash operating expenses from roughly $35 million in 2025 to about $50 million in 2026 as it accelerates commercial expansion and medical initiatives. More than 60% of this spend is expected in the first half of the year, leading to heavier near‑term cash burn as the company invests ahead of anticipated revenue gains.

Revenue and Cash Flow Timing Variability

Management cautioned that revenue and cash flows can be lumpy because of high per‑patient revenue and the timing of receivable collections, as seen in Q4 when cash flows were temporarily pressured. These timing dynamics mean quarter‑to‑quarter cash balances may be volatile even if underlying demand for the product remains on a positive trajectory.

Delayed International Revenue Scale and Ramp Risk

Although European launches are underway, Fennec does not expect material royalty and milestone contributions from Norgine until the latter half of 2026, limiting near‑term international revenue. The company also flagged execution risk around its commercial hiring ramp, noting that if new field teams take longer than expected to reach productivity, the financial benefits of expansion could be pushed out.

Guidance and Forward‑Looking Outlook

Management reiterated that 2025 net product sales reached $44.6 million with Q4 at $13.8 million and ended the year with $36.8 million in cash and no debt, expecting positive operating cash flow in Q1 2026. For 2026, Fennec forecasts cash OpEx of about $50 million, gross‑to‑net near 85%, mid‑single‑digit COGS, flat noncash stock comp, and meaningful revenue uplift in the back half from additional hires and Norgine’s 8–10 planned launches, with the long AYA opportunity and extended exclusivity underpinning the growth case.

Fennec’s earnings call painted the picture of a company trading higher short‑term cost intensity for potentially durable, high‑margin growth anchored by strong exclusivity and expanding clinical validation. For investors, the key watchpoints will be execution on the commercial ramp, the timing of international contributions, and the company’s ability to translate its growing patient base into sustained cash generation across 2026 and beyond.